<DOC>
	<DOC>NCT02489344</DOC>
	<brief_summary>Primary Objective: To assess the long-term safety of GZ/SAR402671 in adult male patients with Fabry disease who previously completed study ACT13739. Secondary Objective: To assess the long-term effect of GZ/SAR402671 on pharmacodynamic and exploratory efficacy endpoints in adult male patients with Fabry disease who previously completed study ACT13739.</brief_summary>
	<brief_title>Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Na√Øve Adult Male Patients With Fabry Disease</brief_title>
	<detailed_description>The total duration of study period will be up to 31 months.</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>Inclusion criteria : Male patient with Fabry disease who previously completed study ACT13739. Patients, willing and able to provide signed informed consent. Sexually active patients, willing to practice true abstinence in line with their preferred and usual lifestyle or using two acceptable effective methods of contraception. Exclusion criteria : Patients, in the opinion of the Investigator, unable to adhere to the requirements of the study. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>